AR105047A1 - METHODS FOR THE TREATMENT OF WOMEN BY THE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH A BUPROPION AND TRAZODONA COMBINATION TREATMENT - Google Patents

METHODS FOR THE TREATMENT OF WOMEN BY THE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH A BUPROPION AND TRAZODONA COMBINATION TREATMENT

Info

Publication number
AR105047A1
AR105047A1 ARP160101828A ARP160101828A AR105047A1 AR 105047 A1 AR105047 A1 AR 105047A1 AR P160101828 A ARP160101828 A AR P160101828A AR P160101828 A ARP160101828 A AR P160101828A AR 105047 A1 AR105047 A1 AR 105047A1
Authority
AR
Argentina
Prior art keywords
treatment
hsdd
bupropion
women
methods
Prior art date
Application number
ARP160101828A
Other languages
Spanish (es)
Inventor
G Sitchon Nick
Meston Cindy
Katz Molly
Drogatis Leonard
Taylor Segraves Robert
Clayton Anita
E Pyke Robert
Original Assignee
S1 Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR105047(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S1 Biopharma Inc filed Critical S1 Biopharma Inc
Publication of AR105047A1 publication Critical patent/AR105047A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para el tratamiento de mujeres por el trastorno de deseo sexual hipoactivo (HSDD) con tratamientos diarios orales de combinaciones de dosis baja y dosis alta de trazodona y bupropion.Methods for the treatment of women with hypoactive sexual desire disorder (HSDD) with daily oral treatments of low dose and high dose combinations of trazodone and bupropion.

ARP160101828A 2016-06-17 2016-06-21 METHODS FOR THE TREATMENT OF WOMEN BY THE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH A BUPROPION AND TRAZODONA COMBINATION TREATMENT AR105047A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351904P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
AR105047A1 true AR105047A1 (en) 2017-08-30

Family

ID=57758862

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP160101856A AR105087A1 (en) 2016-06-17 2016-06-21 METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH THE BUPROPION AND TRAZODONA COMBINATION TREATMENT
ARP160101828A AR105047A1 (en) 2016-06-17 2016-06-21 METHODS FOR THE TREATMENT OF WOMEN BY THE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH A BUPROPION AND TRAZODONA COMBINATION TREATMENT

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP160101856A AR105087A1 (en) 2016-06-17 2016-06-21 METHODS FOR THE TREATMENT OF WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH THE BUPROPION AND TRAZODONA COMBINATION TREATMENT

Country Status (9)

Country Link
KR (1) KR20170142797A (en)
AR (2) AR105087A1 (en)
AU (1) AU2016204151A1 (en)
CA (1) CA2933921A1 (en)
CL (1) CL2016001597A1 (en)
MX (1) MX2016008272A (en)
PE (1) PE20180023A1 (en)
UY (1) UY36742A (en)
WO (1) WO2017218018A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897864A (en) * 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
KR20070014184A (en) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 New pharmaceutical compositions for the treatment of sexual disorders ii
CN101410112A (en) * 2006-03-24 2009-04-15 惠氏公司 New therapeutic combinations for the treatment of depression
SG11201500919PA (en) * 2012-08-06 2015-04-29 S1 Pharmaceuticals Inc Treatment regimens

Also Published As

Publication number Publication date
WO2017218018A1 (en) 2017-12-21
UY36742A (en) 2016-12-30
KR20170142797A (en) 2017-12-28
MX2016008272A (en) 2017-12-18
AR105087A1 (en) 2017-09-06
CA2933921A1 (en) 2017-12-17
PE20180023A1 (en) 2018-01-09
AU2016204151A1 (en) 2018-01-18
CL2016001597A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
CL2017002996A1 (en) Tetra-substituted alkene compounds and their use
TWD187898S (en) Massage apparatus
CL2019001685A1 (en) Amino acid compositions and methods for the treatment of diseases and muscular disorders.
BR112017008659A2 (en) ? gip agonist methods and compounds?
CO2017001493A2 (en) Kits comprising tigit inhibitors and anticancer agents
CL2017000156A1 (en) Procedures for the treatment of paramyxovirus.
NI201500062A (en) ADJUVANT THERAPY WITH KINASE INHIBITORS FROM THE TEC FAMILY
BR112017009497A2 (en) aadc polynucleotides for the treatment of parkinson's disease
CL2015002641A1 (en) Method for the treatment of parkinson's disease.
ES2765949T8 (en) Therapy involving antibodies to claudin 18.2 for cancer treatment
CL2019001996A1 (en) Therapeutic uses of an insect powder.
CL2017000050A1 (en) Combination Therapy for Cancer
CO2018013020A2 (en) Pharmaceutical combinations for cancer treatment
DOP2017000098A (en) HETEROCYCLIC COMPOUND
UY35328A (en) TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
CL2017000845A1 (en) Lysine Gingipain Inhibitors
CO2018012180A2 (en) Treatment methods for cholestatic and fibrotic diseases
CL2016000019A1 (en) Compounds derived from deuterated dihydroxyphenyl or a salt thereof; pharmaceutical composition that comprises them and their use for the treatment of neurotransmitter-mediated disorders such as hypotension, sleep disorders, Alzheimer's disease and depression.
BR112017013286A2 (en) isoxazoline compound, and use of an isoxazoline compound.
PE20230495A1 (en) VACCINATION WITH THE ALPHA 3 DOMAIN OF MICA/B FOR THE TREATMENT OF CANCER
NI201700066A (en) LOW DOSE A2A ANTAGONISTS FOR THE TREATMENT OF ADHD AND PARKINSON'S DISEASE
CR20160369A (en) COMPOSITIONS FOR USE IN THE TREATMENT OF ALLERGIC AFFECTIONS
CL2020000586A1 (en) Modulators of enac expression.
AR105047A1 (en) METHODS FOR THE TREATMENT OF WOMEN BY THE HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) WITH A BUPROPION AND TRAZODONA COMBINATION TREATMENT
PE20160649A1 (en) PIDOTIMOD FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH INFLAMMATION

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FB Suspension of granting procedure